Table 2.
Treatment outcomes and laboratory parameters of the study population.
| 3TC/DTG n = 110 |
BIC/FTC/TAF n = 214 |
Total n = 324 |
p-Value | |
|---|---|---|---|---|
| Time of follow-up, months | 19.6 | 27.5 | 24.6 | 0.001 |
| Median (IQR) | (14.2–26.4) | (15.3–32.6) | (14.7–31.4) | |
| Treatment outcomes, n (%) On therapy Discontinuations due to: |
103 (93.6%) | 193 (90.2%) | 296 (91.3%) | 0.295 |
| Failure | 0 (0%) | 0 (0%) | 0 (0%) | |
| Low level viremia | 2 (1.8%) | 2 (0.9%) | 4 (1.2%) | 0.495 |
| Blip | 5 (4.5%) | 25 (11.8%) | 30 (9.3%) | 0.033 |
| Death | 0 (0%) | 3 (1.4%) | 3 (0.9%) | 0.212 |
| Switch | 1 (0.9%) | 11 (5.1%) | 12 (3.7%) | 0.056 |
| Adverse events | 4 (3.6 %) | 5 (2.3%) | 9 (2.8%) | 0.500 |
| Cutaneous | 0 (0%) | 1 (20%) | 1 (11.1%) | |
| Neurological | 1 (25%) | 1 (20%) | 2 (22.2%) | |
| Musculoskeletal | 3 (75%) | 2 (40%) | 4 (44.4%) | |
| Renal | 0 (0%) | 1 (20%) | 2 (22.2%) | |
| CD4+ cell count (cells/μL) baseline, n (%) | 781.5 | 585.0 | 662.0 | <0.0001 |
| Median (IQR) | (598.0–956.0) | (430.0–841.0) | (491.0–892.0) | |
| CD4+ cell count (cells/μL) last control, n (%) | 762 | 651.0 | 693.0 | 0.002 |
| Median (IQR) | (580.0–1014.0) | (473.0–904.0) | (517.0–950.0) | |
| HIV-RNA ˂ 50 cells/μL last control, n (%) | 109 (99.1%) | 205 (97.2%) | 314 (97.8%) | 0.260 |
| Delta Triglycerides last control-baseline, mg/dL Median (IQR) |
−11 (−48, 13) | −14 (−52, 12) | −13 (−50, 12) | 0.775 |
| Delta LDL last control-baseline, mg/dL Median (IQR) |
−2.3 (−29.1, 16) | −1 (−22, 15.8) | −1.5 (−23.4, 15.8) | 0.682 |
| Delta Cholesterol last control-baseline, mg/dL Median (IQR) |
−2 (−36, 20) | −7 (−26, 13) | −6 (−28, 14) | 0.767 |
| Delta BMI last control-baseline, kg/m2 Median (IQR) |
0.0 (0.9, 0.8) | 0.0 (−0.9, 0,7) | 0.0 (−0.9, 0.7) | 0.993 |
LDL: low-density lipoprotein; BMI: body mass index; IQR: interquartile range.